Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)
Innate Pharma posted quarterly Other Non-Current Liabilities of $386462.4 for Q4 2025, up 31.99% year-on-year from $292795.1 in Q4 2024, and down 25.78% on a QoQ basis from $520701.5 in Q2 2025.
Innate Pharma (IPHA) has 9 years of Other Non-Current Liabilities data on file, last reported at $386462.4 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 31.99% year-over-year to $386462.4; the trailing twelve-month figure through Dec 2025 stood at $386462.4 (up 31.99% YoY), and the FY2025 full-year result was $386462.4, up 31.99% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $386462.4, down from $520701.5 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $648791.8 in Q4 2023 and bottomed at $202009.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $304700.0 (2024), against an average of $373684.9.
- The widest annual swing landed in 2023, when Other Non-Current Liabilities surged 221.17%; it then slumped 54.87% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $289424.7 in 2021, then sank by 30.2% to $202009.0 in 2022, then soared by 221.17% to $648791.8 in 2023, then plunged by 54.87% to $292795.1 in 2024, then jumped by 31.99% to $386462.4 in 2025.
- The last three Other Non-Current Liabilities figures came in at $386462.4 (Q4 2025), $520701.5 (Q2 2025), and $292795.1 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 386,462.45 |
| Jun 30, 2025 | 520,701.46 |
| Dec 31, 2024 | 292,795.14 |
| Jun 30, 2024 | 316,604.95 |
| Dec 31, 2023 | 648,791.77 |
| Jun 30, 2023 | 537,928.65 |
| Dec 31, 2022 | 202,008.98 |
| Jun 30, 2022 | 269,965.34 |
| Dec 31, 2021 | 289,424.65 |
| Jun 30, 2021 | 272,165.34 |
| Dec 31, 2020 | 263,496.06 |
| Jun 30, 2020 | 288,582.55 |
| Dec 31, 2019 | 157,178.05 |
| Dec 31, 2018 | 43,373.06 |
| Dec 31, 2017 | 1.19 Mn |